Spotlight on the ASC4FIRST Study: A Deeper Dive With Karen Seiter, MD
Dr Seiter received compensation from Novartis Pharmaceuticals Corporation for her participation.
Unmet Needs in CML
Explore unmet needs in adult patients with newly diagnosed Ph+ CML-CP and how SCEMBLIX can provide an additional 1L treatment option.
Uncovering a Ground-breaking Study Design
The innovative ASC4FIRST study design evaluated SCEMBLIX vs current standard-of-care TKIs in adult patients with newly diagnosed Ph+ CML-CP.
Standard-of-care TKIs: Imatinib, nilotinib, dasatinib, or bosutinib.
Investigating the Clinical Data Supporting SCEMBLIX
Learn about the SCEMBLIX efficacy and safety/tolerability profile in adult patients with newly diagnosed Ph+ CML-CP as evaluated in the ASC4FIRST study, including key findings on primary and secondary end points.
Investigating the Safety Data
Dive into the safety and tolerability profile findings from the ASC4FIRST study analyzing SCEMBLIX and current standard-of-care TKIs.
Real Patients. Real Stories.
Individual results may vary.
Meet Albert
Albert shares his experience navigating his CML diagnosis and treatment journey, and how he stayed positive.
Meet Jen
Jen shares her experience navigating her CML diagnosis and treatment journey, and how she moved forward.
Meet Amanda
Amanda shares her experience navigating her CML diagnosis and treatment journey, and how she stayed present.